ProKidney Announces Four Abstracts Selected for Presentation at the American Society of Nephrology's Kidney Week 2023GlobeNewsWire • 10/30/23
ProKidney Corp. (PROK) Loses -54.93% in 4 Weeks, Here's Why a Trend Reversal May be Around the CornerZacks Investment Research • 10/17/23
ProKidney to Participate in Fireside Chat at the Morgan Stanley Global Healthcare ConferenceGlobeNewsWire • 09/05/23
ProKidney Reports Second Quarter Financial Results and Recent Corporate HighlightsGlobeNewsWire • 08/10/23
ProKidney Announces Closing of Purchase of Manufacturing Facility in Greensboro, NCGlobeNewsWire • 07/18/23
ProKidney Appoints Bruce Culleton, MD, as Executive Vice President, Clinical Development and CommercializationGlobeNewsWire • 07/15/23
ProKidney to Participate in Fireside Chat at the Jefferies Healthcare ConferenceGlobeNewsWire • 06/01/23
ProKidney Reports First Quarter Financial Results and Recent Corporate HighlightsGlobeNewsWire • 05/11/23
ProKidney Reports Fourth Quarter Financial Results and Recent Corporate HighlightsGlobeNewsWire • 03/28/23
ProKidney Announces Publication of Trial Design for Phase 2 Multicenter Clinical Trial of REACT for Late Stage 4 Diabetes-Related Chronic Kidney DiseaseGlobeNewsWire • 01/10/23
ProKidney Reports Third Quarter 2022 Financial Results and Recent Corporate HighlightsGlobeNewsWire • 11/14/22
ProKidney Receives Allowance from the UK Medicines and Healthcare Products Regulatory Agency (MHRA) for proact 1 (REGEN-006) and EMA Scientific Advice on Phase 3 Protocols of REACT for Diabetic Chronic Kidney DiseaseGlobeNewsWire • 11/03/22
ProKidney Announces Multiple Abstracts Selected for Presentation at the American Society of Nephrology's Kidney Week 2022GlobeNewsWire • 10/14/22